A medicine for treating arthritis caused by gout

Abstract

To solve the problems of the prior art, the application provides a medicine for treating arthritis caused by gout, which is prepared by the following method: step 1, preparing, in mass fraction, 10-30 parts of rhubarb, 5-20 parts of scutellaria, 5-15 parts of radix glechomae, 5-20 parts of ipomoea nil, 3-12 parts of coptis, and 8-20 parts of phellodendron; step 2, grinding the medicine prepared in step S1 into powder, and obtaining mixed medicine powder after uniform mixing; and step 3, adding a blending component to the mixed medicine powder to prepare a paste, thereby obtaining the medicine for treating arthritis caused by gout. The medicine is an external medicine, and compared with the internal medicine, the external medicine has the advantages of simple operation, low price and high patient acceptance. In addition, the medicine has the advantages of fast effect and short treatment cycle, and has good therapeutic effect on joint swelling and pain caused by arthritis caused by gout.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a drug for treating arthritis caused by gout. Background Technology

[0002] Gouty arthritis (GA) is closely related to genetic and environmental factors. Hyperuricemia is the biochemical basis of gout attacks. During an acute attack, changes in blood uric acid concentration occur under the influence of various factors, leading to the deposition of urate crystals in the joint capsule and other tissues. This induces leukocyte chemotaxis and the release of various inflammatory factors, resulting in a local aseptic inflammatory response. Clinically, it manifests as local redness, swelling, pain, and functional impairment in the joints and soft tissues. It is a common metabolic disease in clinical practice, with its incidence increasing year by year and the age of onset becoming younger. During an attack, the joint pain is unbearable, and in the later stages of the disease, it is prone to complications such as hypertension, diabetes, heart disease, and kidney disease. In severe cases, it can even lead to disability, seriously affecting patients' lives, work, study, and physical health.

[0003] Currently, there is no cure for gouty arthritis. For acute attacks, nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and glucocorticoids are commonly used for symptomatic treatment. While these methods effectively alleviate joint swelling and pain to some extent, long-term use presents with contraindications, side effects, and high treatment costs. Traditional Chinese medicine treatment for acute gouty arthritis primarily uses oral medications that clear heat and dampness, and promote blood circulation and remove blood stasis. However, these medications have drawbacks such as poor taste, inconvenient preparation, and slow onset of action, and can easily cause gastrointestinal adverse reactions such as bloating and diarrhea. Summary of the Invention

[0004] This invention addresses the problems existing in the prior art by providing a drug for treating arthritis caused by gout, which is prepared by the following method:

[0005] Step 1: Prepare the following ingredients by weight: 10-30 parts rhubarb, 5-20 parts scutellaria baicalensis, 5-15 parts clematis chinensis, 5-20 parts five-clawed golden dragon, 3-12 parts coptis chinensis, and 8-20 parts phellodendron chinense.

[0006] Step 2: Grind the medicine prepared in step S1 into powder, mix it evenly to obtain mixed medicine powder.

[0007] Step 3: Add the blending components to the mixed powder to make a paste, thus obtaining the drug for treating arthritis caused by gout.

[0008] Furthermore, in step S1, rhubarb, five-clawed golden dragon, coptis, and phellodendron are used as the first component, and clematis and scutellaria are used as the second component; the distribution ratio of the first component and the second component satisfies the following mass ratio: first component: second component = 2-3:1.

[0009] Furthermore, step S1 also includes 1-30 parts of Glauber's salt by mass.

[0010] Furthermore, in step S1, rhubarb, five-clawed golden dragon, coptis, and phellodendron are used as the first component, clematis and scutellaria are used as the second component, and mirabilite is used as the third component. The distribution ratio of the first component, the second component, and the third component satisfies the following mass ratio: first component: second component: third component = 2-3:1:0.2-0.4.

[0011] Furthermore, the third component also includes: 1-20 parts of witch hazel.

[0012] Furthermore, in the third component, by mass parts, Glauber's salt:witch hazel = 1:0.6-0.8.

[0013] Furthermore, step 3 includes:

[0014] Step 3.1 Place the mixed powder in a magnetization device and magnetize it for 1-2 hours to obtain magnetized mixed powder;

[0015] Step 3.2 Add the blending components to the magnetized mixed powder to prepare a paste, thereby obtaining the drug for treating arthritis caused by gout.

[0016] Furthermore, the blending components include: physiological saline, turpentine oil, or honey.

[0017] The advantages of this invention are:

[0018] 1. This invention is an external treatment drug, which, compared with current oral drugs, is simple to operate, inexpensive, and highly acceptable to patients.

[0019] 2. This invention has a rapid onset of action and a short treatment cycle, and has a good therapeutic effect on joint swelling and pain caused by arthritis induced by gout.

[0020] 3. This invention has high selectivity and is an external, localized drug application. The drug does not directly enter the bloodstream, which can effectively avoid the toxic effects of the drug on the liver and other organs. Detailed Implementation

[0021] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0022] This invention provides, by way of example, a medicament for treating arthritis caused by gout, which is prepared by the following method:

[0023] Step 1: Prepare the following ingredients by weight: 10-30 parts rhubarb, 5-20 parts scutellaria baicalensis, 5-15 parts clematis chinensis, 5-20 parts five-clawed golden dragon, 3-12 parts coptis chinensis, and 8-20 parts phellodendron chinense.

[0024] Step 2: Grind the medicine prepared in step S1 into powder, mix it evenly to obtain mixed medicine powder.

[0025] Step 3: Add the blending components to the mixed powder to make a paste, thus obtaining the drug for treating arthritis caused by gout.

[0026] Gouty arthritis falls under the category of "Bi syndrome" in traditional Chinese medicine. Later generations of physicians also called it "Li Jie" or "Bai Hu Bing". Zhu Danxi of the Yuan Dynasty first proposed the name of gout. Zhu Liangchun, a famous physician in modern times, combined the pathogenesis of gout and called it "Zhuo Yu Bi".

[0027] Yi medicine believes that the occurrence and development of this disease are closely related to toxic pathogens. It is a syndrome of deficiency in the root and excess in the branch. The excess in the branch is mainly due to the internal accumulation of toxic pathogens such as dampness, heat, turbidity, blood stasis, and "shen" (a type of toxic substance). The deficiency in the root is mainly manifested in the insufficiency of the clear and turbid qi in the spleen, stomach, kidney, and liver. Due to the internal accumulation of damp-heat toxic pathogens and the external invasion of wind-cold-dampness "shen" toxic pathogens, coupled with the weakness of the human body and the imbalance of clear and turbid qi, the two combine to obstruct the circulation of qi and blood in the body, causing the imbalance of the five elements and the dysfunction of the body's organs. The disorder of the circulation of clear and turbid qi manifests as symptoms such as local joint swelling, knife-like pain, and burning heat.

[0028] In this invention:

[0029] Five-clawed golden dragon has a bitter taste and warm properties. It enters the lung pathway and dispels wind and dampness, invigorates blood circulation and unblocks the meridians.

[0030] The herb *Clematis chinensis* has a bitter and spicy taste, is hot in nature, and enters the stomach and kidney channels. It dispels cold and relieves pain, dispels wind and dampness, and invigorates blood circulation.

[0031] Scutellaria baicalensis is bitter and cold in nature. It enters the lung, liver, gallbladder, stomach, and large intestine pathways, and clears heat, drains fire, dries dampness, and detoxifies.

[0032] Rhubarb is bitter and cold in nature, and it enters the stomach, large intestine, liver, and pancreas. It has the effects of clearing heat and detoxifying, purging and relieving constipation, and promoting blood circulation and removing blood stasis.

[0033] Coptis chinensis has a bitter taste and cold nature. It enters the heart, liver, and large intestine pathways and has the functions of clearing heat and drying dampness, detoxifying and relieving itching.

[0034] Phellodendron bark is bitter and cold in nature. This invention selects it for its functions of clearing heat and drying dampness, detoxifying and healing sores.

[0035] The combination of the above-mentioned drugs restores the balance between clear and turbid qi, ensures smooth flow of qi, removes dampness and heat, thereby relieving the symptoms of redness, swelling, heat and pain in the joints associated with damp-heat accumulation syndrome in gouty arthritis.

[0036] Furthermore, modern pharmacological studies have shown that *Gynostemma pentaphyllum* has the effects of dispelling wind and dampness, relieving pain and reducing swelling. *Clematis chinensis* has anti-inflammatory and analgesic effects. Baicalin and baicalein contained in *Scutellaria baicalensis* can interfere with the metabolic pathway of arachidonic acid and inhibit cytokine activity, thereby producing analgesic and anti-inflammatory effects. Emodin, the main component of rhubarb, can activate the antioxidant Nrf2 pathway, thereby reducing NF-κB-mediated inflammatory signals and thus playing an anti-inflammatory and analgesic role. *Coptis chinensis* has antibacterial and vasodilatory effects.

[0037] The topical dressing obtained by using the combination of the drugs in this patent is not only simple to prepare, but also has a very good therapeutic effect on arthritis caused by gout.

[0038] Furthermore, this patented drug is applied directly to the arthritis site, exhibiting strong selectivity. As it is an external, localized medication, the drug does not directly enter the bloodstream, effectively avoiding toxic effects on the liver and other organs.

[0039] The present invention provides an exemplary method for the formulation of drugs in step S1, specifically: rhubarb, five-clawed golden dragon, coptis, and phellodendron are used as the first component, and clematis and scutellaria are used as the second component; the ratio of the first component to the second component satisfies the following mass ratio: first component: second component = 2-3:1.

[0040] The applicant's research shows that, with this formulation, the overall effectiveness of the drug can reach 100%, the efficacy rate is relatively high, and the cure rate is improved to a certain extent.

[0041] The present invention provides an exemplary composition of the drug in step S1, specifically: 10-30 parts of rhubarb, 5-20 parts of scutellaria baicalensis, 5-15 parts of clematis chinensis, 5-20 parts of five-clawed golden dragon, 3-12 parts of coptis chinensis, 8-20 parts of phellodendron chinense, and 1-30 parts of mirabilite.

[0042] The addition of Glauber's salt can enhance the efficacy of the drug of this invention, thereby improving the drug's efficacy and cure rate.

[0043] The present invention provides an exemplary method for the formulation of drugs in step S1, specifically: rhubarb, five-clawed golden dragon, coptis, and phellodendron are used as the first component; clematis and scutellaria are used as the second component; and mirabilite is used as the third component. The first component, the second component, and the third component are configured in the following mass ratio: first component: second component: third component = 2-3:1:0.6-0.8.

[0044] Through research, the applicant found that specific amounts of Glauber's salt can significantly improve the efficacy of the drug, thereby further enhancing its effectiveness, significantly increasing the cure rate, and significantly improving its anti-inflammatory effect.

[0045] The present invention provides an exemplary composition of the drug in step S1, specifically including: 10-30 parts of rhubarb, 5-20 parts of scutellaria baicalensis, 5-15 parts of clematis chinensis, 5-20 parts of five-clawed golden dragon, 3-12 parts of coptis chinensis, 8-20 parts of phellodendron chinense, 1-30 parts of mirabilite, and 1-20 parts of witch hazel.

[0046] This invention provides an exemplary method for the formulation of the drugs in step S1, specifically: rhubarb, five-clawed golden dragon (a type of herb), coptis, and phellodendron bark are used as the first component; *Clematis chinensis* and *Scutellaria baicalensis* are used as the second component; and mirabilite and witch hazel are used as the third component. The mass ratio of the first, second, and third components satisfies the following: First component: Second component: Third component = 2-3:1:0.2-0.4. Furthermore, in the third component, by mass fraction, mirabilite: witch hazel = 1:0.6-0.8.

[0047] Through research, the applicant discovered that adding a specific amount of witch hazel and Glauber's salt to the third component can produce a synergistic effect, thereby further improving the synergistic effect of the third component on the drug of this invention.

[0048] This invention provides an exemplary drug processing method, wherein step 3 includes:

[0049] Step 3.1 Place the mixed powder in a magnetization device and magnetize it for 1-2 hours to obtain magnetized mixed powder;

[0050] Step 3.2 Add the blending components to the magnetized mixed powder to prepare a paste, thereby obtaining the drug for treating arthritis caused by gout.

[0051] The applicant's research has shown that by magnetizing the mixed drug powder, the drug's effective time can be significantly reduced.

[0052] This invention provides an exemplary blending component comprising: physiological saline, turpentine oil, or honey. Using this blending component results in less irritation to the human body and can effectively promote…

[0053] The following detailed description of this patented drug is provided in conjunction with specific embodiments and clinical efficacy data.

[0054] Example 1

[0055] A drug for treating arthritis caused by gout is prepared by the following method:

[0056] Step 1: Prepare the following ingredients by weight: 15 parts rhubarb, 10 parts scutellaria baicalensis, 10 parts clematis chinensis, 10 parts ginseng, 10 parts coptis chinensis, and 12 parts phellodendron chinense. The following conditions must be met: rhubarb, ginseng, coptis chinensis, and phellodendron chinense constitute the first component; clematis chinensis and scutellaria baicalensis constitute the second component; the mass ratio of the first component to the second component must satisfy: first component: second component = 2.35:1.

[0057] Step 2: Grind the medicine prepared in step S1 into powder, mix it evenly to obtain mixed medicine powder.

[0058] Step 3: Add the blending components to the mixed powder to make a paste, thus obtaining the drug for treating arthritis caused by gout.

[0059] Example 2

[0060] A drug for treating arthritis caused by gout is prepared by the following method:

[0061] Step 1: Prepare the following ingredients by weight: 15 parts rhubarb, 10 parts scutellaria baicalensis, 10 parts clematis chinensis, 10 parts ginseng, 10 parts coptis chinensis, 12 parts phellodendron chinense, and 15 parts mirabilite. The following components should be used as the first component: rhubarb, ginseng, coptis chinensis, and phellodendron chinense; the following components should be used as the second component: clematis chinensis and scutellaria baicalensis; and the following component should be used as the third component. The mass ratio of the first, second, and third components should be 2.35:1:0.75.

[0062] Step 2: Grind the medicine prepared in step S1 into powder, mix it evenly to obtain mixed medicine powder.

[0063] Step 3: Add the blending components to the mixed powder to make a paste, thus obtaining the drug for treating arthritis caused by gout.

[0064] Example 3

[0065] A drug for treating arthritis caused by gout is prepared by the following method:

[0066] Step 1: Prepare the following components by weight: 15 parts rhubarb, 10 parts scutellaria baicalensis, 10 parts clematis chinensis, 10 parts scutellaria barbata, 10 parts coptis chinensis, 12 parts phellodendron chinense, 9 parts mirabilite, and 6 parts witch hazel. The components should satisfy the following: rhubarb, scutellaria barbata, coptis chinensis, and phellodendron chinense constitute the first component; clematis chinensis and scutellaria baicalensis constitute the second component; and mirabilite and witch hazel constitute the third component. The weight ratio of the first, second, and third components should be: first component: second component: third component = 2.35:1:0.75. Furthermore, within the third component, the weight ratio of mirabilite to witch hazel is 1:0.67.

[0067] Step 2: Grind the medicine prepared in step S1 into powder, mix it evenly to obtain mixed medicine powder.

[0068] Step 3: Add the blending components to the mixed powder to make a paste, thus obtaining the drug for treating arthritis caused by gout.

[0069] Experimental plan:

[0070] 1. The patients were those with gouty arthritis who visited the rheumatology outpatient clinic. The sampling group consisted of adults.

[0071] 2. Sampling Standards:

[0072] (1) Meets the diagnostic criteria of Western medicine and the diagnostic criteria of syndrome in traditional Chinese and Yi medicine;

[0073] (2) The course of the illness was within 48 hours and no treatment drugs were used.

[0074] (Including nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticoids);

[0075] (3) Age between 18 and 70 years old, gender not limited;

[0076] (4) VAS score ≥ 4 points;

[0077] (5) Women of childbearing age who have no immediate plans to conceive (negative urine pregnancy test within 48 hours before the start of the study) and who are willing to use non-drug contraception during the study period;

[0078] (6) Agree to the relevant treatment measures adopted in this study and are willing to bear the relevant risks that may arise therefrom.

[0079] 3. Treatment plan:

[0080] (1) Basic treatment:

[0081] Follow a low-purine diet, drink more than 2000ml of water daily, avoid strenuous exercise, elevate the affected limb appropriately, and take colchicine tablets orally (produced by Yunnan Botanical Pharmaceutical Co., Ltd., National Drug Approval Number H53020166, specification: 0.5mg x 20 tablets / box), 1 tablet / time, 3 times / day, for a course of 7 days.

[0082] (2) Treatment group:

[0083] For painful joints, apply this patented medication topically once a day for 4-6 hours each time, for a course of 7 days.

[0084] (3) Control group

[0085] For painful joints, apply the mimicry agent externally (the mimicry agent is made into a paste from corn flour, celery powder, and pumpkin powder; the mimicry agent and the patented drug are of the same weight and packaged in the same way). Apply once a day for 4-6 hours each time, for a course of 7 days.

[0086] 4. Observation indicators:

[0087] The scores for symptoms in traditional Chinese and Yi medicine before and after treatment were formulated with reference to the "Traditional Chinese Medicine Diagnosis and Treatment Plan for 22 Specialties and 95 Diseases".

[0088] Laboratory indicators: ESR, CRP, UA.

[0089] And adverse reactions.

[0090] 5. Treatment indicators:

[0091] Based on patient self-reports and doctor's observations, the cases are categorized into three types: cured, significantly effective, effective, and ineffective.

[0092] Recovery: The redness, swelling, and pain in the affected area disappear, and limb movement returns to normal.

[0093] Recovery rate = (Number of recovered patients / Total number of patients) * 100%.

[0094] Significant effect: Pain in the affected area is significantly reduced, redness and swelling are significantly improved, mobility is significantly improved, and there is no obvious pain.

[0095] Effective rate = (Number of cured patients + Number of patients with significant improvement) / Total number of patients * 100%.

[0096] Effective: Pain in the affected area has improved, and redness and swelling have lessened, but pain is still felt during activity.

[0097] Effectiveness rate = (Number of cured patients + Number of patients with significant improvement + Number of patients with effective results) / Total number of patients * 100%.

[0098] Ineffective: No improvement in pain, redness and swelling in the affected area.

[0099] 6. Statistical methods

[0100] SPSS 23.0 statistical software was used for analysis. Quantitative data were expressed as mean plus or minus standard deviation. The t-test is used for normally distributed measurement data, the rank-sum test is used for non-normally distributed measurement data or ordinal data, and the chi-square test is used for count data. A p-value < 0.05 is considered statistically significant.

[0101] The control group consisted of 36 participants, treatment group A (using the drug from Example 1) consisted of 50 participants, treatment group B (using the drug from Example 2) consisted of 50 participants, and treatment group C (using the drug from Example 3) consisted of 50 participants. Clinical efficacy is shown in Table 1, and laboratory indicators before and after treatment are shown in Table 2.

[0102] Table 1. Clinical efficacy of control group and treatment groups A to C

[0103] Group Number of people get well Effective efficient invalid Effectiveness (%) control group 36 0 20 14 2 94 Treatment Group A 50 7 31 12 0 100 Treatment Group B 50 15 26 9 0 100 Treatment group C 50 20 27 3 0 100

[0104] Table 2. Changes in laboratory indicators before and after treatment

[0105]

[0106]

[0107] The experimental results above show that:

[0108] (1) On the basis of basic treatment, the topical application of the combination drugs of the present invention can significantly improve the effectiveness of treatment, and the effectiveness rate can be maintained at 100%.

[0109] (2) Compared with basic treatment methods, the efficacy of the topical application of the combination drugs of the present invention is significantly improved. In the drug combination of Example 1 of the present invention, the cure rate reaches 15% and the efficacy reaches 76%. In the drug combination of Example 2 of the present invention, that is, by adding a specific amount of Glauber's salt to the basis of Example 1, the cure rate can reach 30% and the efficacy can be further improved to 82%. In the drug combination of Example 3 of the present invention, that is, by further adding a specific amount of witch hazel to the basis of Example 2, the cure rate can be further improved to 40% and the efficacy can reach 94%.

[0110] (3) Compared with basic treatment methods, the anti-inflammatory effect of the topical combination of drugs of the present invention is significantly enhanced. Under the drug combination of Example 1 of the present invention, after treatment, the patients' ESR decreased significantly, and CRP decreased to near the normal value. Under the drug combination of Example 2 of the present invention, after treatment, the patients' ESR decreased to near the normal value, and a small number of patients' ESR was relatively high, while CRP could completely decrease to the normal range. Under the drug combination of Example 3 of the present invention, after treatment, the ESR of 49 out of 50 sampled patients decreased to within the normal range, only 1 patient's ESR was 16.42, and the CRP of all patients decreased to the normal range.

[0111] (4) Compared with the basic treatment method, after applying the combination of drugs of the present invention, the patients’ uric acid levels dropped to the normal range after one course of treatment and remained at a low value range.

[0112] Comparative Example 1

[0113] The remaining steps and proportions are the same as in Example 2, except that the amount of the third component added is 5 parts.

[0114] Comparative Example 2

[0115] The remaining steps and proportions are the same as in Example 2, except that the amount of the third component added is 25 parts.

[0116] Comparative Example 3

[0117] The remaining steps and proportions are the same as in Example 3, except that the third component is witch hazel.

[0118] Comparative Example 4

[0119] The remaining steps and proportions are the same as in Example 3, except that the third component consists of 6 parts Glauber's salt and 9 parts witch hazel.

[0120] The number of patients in treatment group D using the drug from Comparative Example 1 was 20, the number of patients in treatment group E using the drug from Comparative Example 2 was 20, the number of patients in treatment group F using the drug from Comparative Example 3 was 20, and the number of patients in treatment group G using the drug from Comparative Example 1 was 20. The clinical efficacy is shown in Table 3.

[0121] Table 3. Clinical efficacy of control group and treatment groups A to G

[0122] Group Number of people get well Effective efficient invalid Effectiveness (%) Treatment Group A 50 7 31 12 0 100 Treatment Group B 50 15 26 9 0 100 Treatment group D 20 3 12 3 0 100 Treatment group E 20 4 12 4 0 100 Treatment group C 50 20 27 3 0 100 Treatment group F 20 3 12 5 0 100 Treatment group G 20 6 12 2 0 100

[0123] As shown in Table 3:

[0124] (1) As can be seen from treatment groups B to E, the addition of the third component, Glauber's salt, can improve the efficacy of the basic formula of this invention. However, when the amount of the third component added is small, although the effect is slightly improved compared to treatment group A, the effect is not significant, and the cure rate is increased by 1%. This is significantly lower than the 16% increase in cure rate after using the specific ratio of the third component in Example 2. At the same time, when the amount of the third component added is large, the treatment effect is improved compared to treatment group A, and the cure rate is increased by 6%. However, this is still lower than the 16% increase in cure rate after using the specific ratio of the third component in Example 2. It can be seen that the addition of the third component can improve the efficacy of the basic formula of this invention, and when the amount of the third component added meets the ratio requirements of this invention, this effect of enhancing efficacy will be very obvious. Increasing or decreasing the amount of the third component will both lead to a decrease in the effect of enhancing efficacy.

[0125] (2) As can be seen from the comparison between treatment group A and treatment group F, when witch hazel is used alone, it does not significantly improve or deteriorate the efficacy of the basic formula of the present invention. Even when the amount of added witch hazel in Comparative Example 3 (treatment group F) reached the amount of added Glauber's salt in Example 2, its effect was only slightly improved compared with Example 1 (treatment group A) without the use of witch hazel.

[0126] (3) As can be seen from the comparison of treatment group C, treatment group F and treatment group G, when witch hazel is used together with Glauber's salt in a specific ratio, it will further enhance the effect of the basic formula drug of the present invention, which is manifested in the cure rate increasing from 30% to 40% and the total effective rate increasing from 82% to 94%, that is, it can produce significant therapeutic effects on the vast majority of patients.

[0127] Example 4

[0128] A drug for treating arthritis caused by gout is prepared by the following method:

[0129] Step 1: Prepare the following ingredients by weight: 15 parts rhubarb, 10 parts scutellaria baicalensis, 10 parts clematis chinensis, 10 parts ginseng, 10 parts coptis chinensis, 12 parts phellodendron chinense, 9 parts mirabilite, and 6 parts witch hazel. The following components should be used as the first component: rhubarb, clematis chinensis, ginseng, coptis chinensis, phellodendron chinense, and mirabilite; scutellaria baicalensis as the second component; and witch hazel as the third component. The mass ratio of the first, second, and third components should be 7:1:0.7.

[0130] Step 2: Grind the medicine prepared in step S1 into powder, mix it evenly to obtain mixed medicine powder.

[0131] Step 3.1 The mixed powder is placed in a magnetization device and magnetized for 2 hours to obtain magnetized mixed powder.

[0132] Step 3.2 Add the blending components to the magnetized mixed powder to prepare a paste, thereby obtaining the drug for treating arthritis caused by gout.

[0133] The treatment group H, using the drug from Example 4, consisted of 50 participants. The clinical efficacy is shown in Table 4, and the time to completion of treatment was recorded, as shown in Table 5. The method for calculating the time to completion of treatment was as follows:

[0134] For patients who are cured within 1.6 days or 6 days, the time of cure shall be the time when the treatment is completed.

[0135] For patients who were not cured within 2.6 days and 6 days, the treatment effect after the completion of treatment on the 7th day was classified as cured, significantly effective, or effective. The time for the completion of treatment for the above patients was counted as 7 days.

[0136] Table 4. Clinical efficacy of treatment group C and treatment group H

[0137] Group Number of people get well Effective efficient invalid Effectiveness (%) Treatment group C 50 20 27 3 0 100 Treatment group H 50 28 21 1 0 100

[0138] Table 5. Statistics of Treatment Completion Time and Number of Individuals in Treatment Groups C and H

[0139] Group one day Two days Three days Four days Five days Six days Seven days Treatment group C 0 0 0 0 3 5 42 Treatment group H 0 0 0 2 5 10 33

[0140] As shown in Tables 4 and 5, with the same drug composition, the therapeutic effect was better after magnetization treatment, with the efficacy rate increasing to 98%. Essentially, all patients could receive effective treatment within one course, and the cure rate reached 56%. Furthermore, observation of cure time revealed that after magnetization treatment, treatment group H not only saw cured patients as early as the fourth day, but also had more cured patients on the fifth and sixth days than treatment group C, meaning more patients could recover without requiring seven days of treatment.

[0141] It should be noted and understood that various modifications and improvements can be made to the invention described in the above detailed description without departing from the spirit and scope of the claims. Therefore, the scope of the claimed solutions is not limited to any specific exemplary teachings given.

Claims

1. A topical medication for treating arthritis caused by gout, characterized in that, It is prepared by the following method: Step 1, prepare by mass fraction: rhubarb 10-30 parts, scute 5-20 parts, radix meliae 5-15 parts, ipomoea nil 5-20 parts, coptis 3-12 parts, phellodendron 8-20 parts, mirabilite 1-30 parts, buckthorn 1-20 parts; Take rhubarb, ipomoea nil, coptis, and phellodendron as the first component, take radix meliae and scute as the second component, and take mirabilite and buckthorn as the third component; the first component, the second component, and the third component are matched in mass ratio as follows: first component: second component: third component = 2-3: 1: 0.6-0.8; In the third component, mirabilite: buckthorn = 1: 0.6-0.8 by mass fraction; Step 2, grind the medicine prepared in step S1 into powder, mix uniformly to obtain mixed medicine powder; Step 3, add blending components to the mixed medicine powder to prepare paste, and obtain the medicine for treating gout-induced arthritis.

2. The medicament for external use according to claim 1, which is for treating arthritis caused by gout. The step 3 includes: Step 3.1, place the mixed medicine powder into a magnetization device for magnetization treatment for 1-2 hours to obtain magnetized mixed medicine powder; Step 3.2, add blending components to the magnetized mixed medicine powder to prepare paste, and obtain the medicine for treating gout-induced arthritis.

3. The medicament for external use according to claim 1, which is for treating arthritis caused by gout. The blending components are physiological saline, turpentine oil, or honey.

Images